Novo Nordisk says experimental drug amycretin show 13% weight loss in trial 

    Related

    Share


    Business & FinanceHealth

    Reuters was first to report on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed that participants had a weight loss of 13.1% after 12 weeks, prompting the company’s shares to rise to record highs and placing it above Tesla by market valuation. 

    Market Impact

    Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously.

    Article Tags

    Topics of Interest: Business & FinanceHealth

    Type: Reuters Best

    Sectors: Business & FinancePharmaceuticals & Healthcare

    Regions: Americas

    Countries: United States

    Win Types: Speed

    Story Types: Exclusive / Scoop

    Media Types: Text

    Customer Impact: Significant National Story



    Source link